Checchi Capital Advisers LLC Decreases Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Checchi Capital Advisers LLC reduced its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 635 shares of the company’s stock after selling 41 shares during the quarter. Checchi Capital Advisers LLC’s holdings in IDEXX Laboratories were worth $263,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Sabal Trust CO acquired a new stake in shares of IDEXX Laboratories in the 4th quarter worth approximately $812,000. JFG Wealth Management LLC purchased a new stake in IDEXX Laboratories during the fourth quarter worth $305,000. FFT Wealth Management LLC acquired a new stake in IDEXX Laboratories in the fourth quarter valued at $227,000. Sterling Investment Advisors Ltd. purchased a new position in shares of IDEXX Laboratories in the fourth quarter valued at $455,000. Finally, BankPlus Trust Department acquired a new position in shares of IDEXX Laboratories during the 4th quarter worth $60,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

IDXX has been the topic of a number of research reports. Morgan Stanley lowered their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. StockNews.com upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Barclays upped their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. Finally, Bank of America raised their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and a consensus target price of $533.75.

Insider Activity at IDEXX Laboratories

In related news, EVP George Fennell sold 9,986 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director M Anne Szostak sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares of the company’s stock, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.11% of the company’s stock.

IDEXX Laboratories Trading Down 3.7 %

Shares of IDXX opened at $441.03 on Friday. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $583.39. The company has a market capitalization of $35.87 billion, a PE ratio of 41.33, a price-to-earnings-growth ratio of 3.41 and a beta of 1.37. The stock has a fifty day moving average of $434.82 and a two-hundred day moving average of $451.84. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.